文献速递鼻科头颈外科

嗜酸性肉芽肿性多血管炎:生物制剂与鼻窦手术治疗鼻息肉的真实世界研究

Eosinophilic Granulomatosis With Polyangiitis: A Real-World Study of Biologics and Sinus Surgery Use for Managing Nasal Polyposis.
PubMed 文献 · Int Forum Allergy Rhinol · 2025-01-21

本研究通过查询Mayo Clinic统一电子病历,纳入2010年1月至2024年1月期间接受生物制剂治疗的80例伴鼻息肉的嗜酸性肉芽肿性多血管炎(EGPA)患者,分析生物制剂处方模式及其对鼻息肉和鼻内镜鼻窦手术(ESS)的影响。结果显示,80例中71例(88.75%)接受过ESS,其中62例(77.5%)在生物制剂治疗前共接受131次ESS;38例(47.5%)在生物制剂治疗期间因难治性鼻息肉接受ESS共47次。生物制剂单药治疗占90%(72例),最常用为美泊利珠单抗(81.9%)。结论认为,生物制剂联合ESS的多学科多模式治疗似乎是控制EGPA鼻息肉的主要手段。

要点

  • 80例伴鼻息肉的EGPA患者中,71例(88.75%)接受过ESS,62例(77.5%)在生物制剂治疗前共接受131次ESS。
  • 生物制剂单药治疗占90%(72例),美泊利珠单抗最常用(81.9%),其次为利妥昔单抗(23.6%)、贝那利珠单抗(18.1%)和度普利尤单抗(12.5%)。
  • 38例(47.5%)在生物制剂治疗期间因难治性鼻息肉接受ESS共47次;单药治疗患者中,美泊利珠单抗组52.5%接受ESS,利妥昔单抗组23.5%,贝那利珠单抗组42.8%,度普利尤单抗组22.2%。

核心结论

  • 生物制剂联合ESS的多学科多模式治疗似乎是控制EGPA鼻息肉的主要手段;美泊利珠单抗是最常用的生物制剂;10%的患者需要双生物制剂治疗。

研究设计与样本

  • 通过查询Mayo Clinic统一电子病历,识别2010年1月至2024年1月期间在任何Mayo Clinic站点接受生物制剂治疗的伴鼻息肉EGPA患者80例,研究生物制剂治疗模式、临床病程、对鼻息肉的影响及ESS实施情况。

主要发现

  • 80例患者中,71例(88.75%)接受过ESS,其中62例(77.5%)在生物制剂治疗前共接受131次ESS。
  • 38例(47.5%)在生物制剂治疗期间因难治性鼻息肉接受ESS共47次。
  • 生物制剂单药治疗占90%(72例);美泊利珠单抗使用率81.9%,利妥昔单抗23.6%,贝那利珠单抗18.1%,度普利尤单抗12.5%。
  • 单药治疗患者中,接受ESS的比例分别为:美泊利珠单抗组52.5%,利妥昔单抗组23.5%,贝那利珠单抗组42.8%,度普利尤单抗组22.2%。

关键数值与推荐

  • 生物制剂单药治疗占90%(72/80),美泊利珠单抗最常用(81.9%)。
  • 双生物制剂治疗用于8例(10%)患者。
  • 生物制剂治疗期间因难治性鼻息肉接受ESS共47次,涉及38例(47.5%)患者。

临床怎么用

  • 原文结论认为,生物制剂联合ESS的多学科多模式治疗似乎是控制EGPA鼻息肉的主要手段;美泊利珠单抗是最常用的生物制剂;10%的患者需要双生物制剂治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND/AIM: Eosinophilic granulomatosis with polyangiitis (EGPA) is a multisystemic disease associated with nasal polyposis. Multiple biologics are used for managing EGPA, including some approved for nasal polyps (NP). This study investigated real-world biologic prescription patterns for EGPA and their impact on NP and endoscopic sinus surgery (ESS) use. METHODS: EGPA patients with NP treated with a biologic at any Mayo Clinic site (January 2010 to January 2024) were identified by querying the unified electronic medical record. Patterns of biologic therapy, clinical course, impact on NP, and performance of ESS were studied. RESULTS: Eighty patients were identified. Overall, 71 of 80 (88.75%) patients underwent ESS, with 62 of 80 (77.5%) undergoing 131 ESS procedures prior to biologic therapy. ESS for recalcitrant NP (47 episodes) was performed on 38 of 80 (47.5%) patients on biologics. Biologic monotherapy was used in 90% (72) of patients; mepolizumab (81.9%) was the most common, followed by rituximab (23.6%), benralizumab (18.1%), and dupilumab (12.5%). Switching of biologics was observed in 28 of 80 patients. Concurrent dual-biologic therapy was used in eight (10%) patients. For patients on single-agent biologic therapy, ESS was performed on 52.5% of patients on mepolizumab, 23.5% on rituximab, 42.8% on benralizumab, and 22.2% on dupilumab. CONCLUSIONS: Multidisciplinary multi-modality treatment with biologics and ESS appeared to be the mainstay of controlling NP in EGPA. Mepolizumab was the most frequently used biologic. Dual biologic therapy was necessary in 10% of patients. Overall, 71 of 80 (88.75%) patients had ESS, with almost half the study population (47.5%) undergoing ESS after initiating biologic treatment.

来源:Int Forum Allergy Rhinol,查看原文。版权归原作者所有。

引用

  1. Kumar N, Jett SD, Gomes PL, et al. Eosinophilic Granulomatosis With Polyangiitis: A Real-World Study of Biologics and Sinus Surgery Use for Managing Nasal Polyposis. Int Forum Allergy Rhinol. 2025. PMID: 39835437. doi:10.1002/alr.23536

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。